A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...
The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune ...
The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — ...
If you smoke and want to quit, call the national quit line at 1-800-784-8669 to speak with a confidential coach. In what ...
“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...
Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...
Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback